Real-World Study Evaluating the Efficacy of Frontline Brentuximab Vedotin Plus Chemotherapy in Newly Diagnosed Patients with Hodgkin Lymphoma: A Retrospective Analysis

Cai, Qingqing; Xia, Yi; Li, Panpan; Zhang, Yuchen; Zou, Qihua; Cai, Jun

doi:10.1182/blood-2022-156400

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-year update of this international randomized phase III study showed a PFS benefit of BV-AVD over the ABVD standard arm (5-year PFS of 82.2% vs. 75.3%, HR 0.69, p = 0.0017) [61]. The benefits of BV-AVD were consistent in different subgroups of patients regardless of treatment response at the interim-PET (PET-2 status), disease stage and other prognostic factors, and they were also confirmed by real-world studies [61][62][63][64]. Moreover, the last 6-year long-term analysis of the trial demonstrated an improved OS for BV-AVD in respect of the standard arm (93.9% and 89.4%, respectively, HR 0.68), thus confirming the higher effectiveness of the immunochemotherapy combination in respect of standard chemotherapy for treatment-naïve advanced stage cHL [65].…”

Section: Bv Plus Chemotherapy Combinationsmentioning

confidence: 55%

Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice

Benevolo Savelli,

Bisio,

Legato

et al. 2024

Cancers

View full text Add to dashboard Cite

Classical Hodgkin Lymphoma (cHL) is a highly curable disease, but around 20% of patients experience progression or relapse after standard frontline chemotherapy regimens. Salvage regimens followed by autologous stem cell transplants represent the historical treatment approach for these cases. In the last decade, with the increasing understanding of cHL biology and tumor microenvironment role in disease course, novel molecules have been introduced in clinical practice, improving outcomes in the relapsed/refractory setting. The anti-CD30 antibody-drug conjugated brentuximab vedotin and PD-1/PD-L1 checkpoint inhibitors represent nowadays curative options for chemorefractory patients, and randomized trials recently demonstrated their efficacy in frontline immune-chemo-combined modalities. Several drugs able to modulate the patients’ T-lymphocytes and NK cell activity are under development, as well as many anti-CD30 chimeric antigen receptor T-cell products. Multiple tumor aberrant epigenetic mechanisms are being investigated as targets for antineoplastic compounds such as histone deacetylase inhibitors and hypomethylating agents. Moreover, JAK2 inhibition combined with anti-PD1 blockade revealed a potential complementary therapeutic pathway in cHL. In this review, we will summarize recent findings on cHL biology and novel treatment options clinically available, as well as promising future perspectives in the field.

show abstract